Abacavir

Research use only, not for human use.

A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS.

A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS.HIV Infection Approved(In Vitro):Abacavir (15 and 150 μM, 0-120 h) inhibits cell growth, affects cell cycle progression, induces senescence and modulates LINE-1 mRNA expression in prostate cancer cell lines.Abacavir (15 and 150 μM, 18 h) significantly reduces cell migration and inhibits cell invasion.Abacavir induces fat apoptosis.(In Vivo):Abacavir (100 and 200 mg/kg, p.o.; 4 h) dose-dependently promoted thrombus formation.Abacavir (50 mg/kg/d; i.p.; 14 d) with 0.1 mg/kg/d Decitabine (HY-A0004) enhances survival of high-risk medulloblastoma-bearing mice.

Abacavir (15 and 150 μM, 0-120 h) inhibits cell growth, affects cell cycle progression, induces senescence and modulates LINE-1 mRNA expression in prostate cancer cell lines.Abacavir (15 and 150 μM, 18 h) significantly reduces cell migration and inhibits cell invasion.Abacavir induces fat apoptosis. Cell Proliferation Assay Cell Line:PC3, LNCaP and WI-38 Concentration:15 and 150 μM Incubation Time:0, 24, 48, 72 and 96 h Result:Showed a dose-dependent growth inhibition on PC3 and LNCaP.Cell Cycle Analysis Cell Line:PC3 and LNCaP Concentration:150 μM Incubation Time:0, 18, 24, 48, 72, 96 and 120 h Result:Caused a very high accumulation of cells in S phase in PC3 and LNCaP cells, and G2/M phase increment was observed in PC3 cells.Cell Migration Assay Cell Line:PC3 and LNCaP Concentration:15 and 150 μM Incubation Time:18 h Result:Significantly reduced cell migration.Cell Invasion AssayCell Line:PC3 and LNCaP Concentration:15 and 150 μM Incubation Time:18 h Result:Significantly inhibited cell invision.

Abacavir (100 and 200 mg/kg, p.o.; 4 h) dose-dependently promoted thrombus formation.Abacavir (50 mg/kg/d; i.p.; 14 d) with 0.1 mg/kg/d Decitabine (HY-A0004) enhances survival of high-risk medulloblastoma-bearing mice. Animal Model:Male mice (9-weeks old, 22-30 g) - wild-type (WT) C57BL/6 or homozygous knockout (P2rx7 KO, B6.129P2-P2rx7tm1Gab/J) Dosage:2.5, 5 and 7.5 μg/mL, 100 μL or 100 and 200 mg/kg Administration:Intrascrotal or oral administration for 4 h Result:Dose-dependently promoted thrombus formation.Animal Model:NSGTM mice, patient-derived xenograft (PDX) cells of non-WNT/non-SHH, Group 3 and of SHH/ TP53-mutated medulloblastomaDosage:50 mg/kg/d with 0.1 mg/kg/d Decitabine Administration:Intraperitoneal injection, daily for 14 days Result:Inhibited tumor growth and enhanced mouse survival.

ABC, Ziagen | Epzicom | Abacavir

Microbiology/Virology

HIV

HIV-1reverse-transcriptase

Infection

HIV Infection

136470-78-5

286.3323

C14H18N6O

>98% (HPLC)

DMSO: ≥ 3 mg/mL

C1CC1NC2=NC(=NC3=C2N=CN3[C@@H]4C[C@@H](C=C4)CO)N

2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S,4R)-

(-20℃)

With Ice Pack

≥ 2 years